This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Owens & Minor (OMI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $37.75, marking a -1.87% move from the previous day.
Top Ranked Growth Stocks to Buy for March 22nd
by Zacks Equity Research
UEIC, HRI, OMI, and REPYY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 22, 2021
Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.
NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.
Penumbra (PEN) Launches INDIGO System Lightning 7 in US
by Zacks Equity Research
Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.
Zacks.com featured highlights include: Vishay Intertechnology, PVH Corp, Owens & Minor and Sanmina Corp
by Zacks Equity Research
Zacks.com featured highlights include: Vishay Intertechnology, PVH Corp, Owens & Minor and Sanmina Corp
Buy These 7 Stocks With Low P/B Ratio to Boost Returns
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects. PVH Corp. (PVH), Honda Motor (HMC), Owens & Minor (OMI), ArcelorMittal (MT), Hologic (HOLX), ASE Technology Holding (ASX) and Goldman Sachs (GS) are good stocks to add.
Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient
by Zacks Equity Research
Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.
Create a Standout Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Vishay Intertechnology (VSH), PVH Corp. (PVH), Owens & Minor (OMI) and Sanmina Corporation (SANM) boast low P/CF ratio.
Top Ranked Growth Stocks to Buy for March 17th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 17th
Owens & Minor (OMI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $35.98, marking a -1.72% move from the previous day.
Top Ranked Growth Stocks to Buy for March 15th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 15th
Buy These 5 Low-Beta Stocks & Combat the Choppy Market
by Nilanjan Banerjee
Low-beta stocks may be able to help sail through the choppy market conditions.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.
Earnings Estimates Rising for Owens & Minor (OMI): Will It Gain?
by Zacks Equity Research
Owens & Minor (OMI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Top Ranked Growth Stocks to Buy for March 9th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 9th
Abbott's (ABT) Diagnostics Arm to Gain From New & Updated EUAs
by Zacks Equity Research
Abbott's (ABT) Alinity m SARS-CoV-2 test set to detect COVID-19 in individuals who do not have symptoms.
Boston Scientific (BSX) Buys Lumenis to Expand in Urology
by Zacks Equity Research
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
Abbott (ABT) Gets Canadian Nod for FreeStyle Libre Expanded Use
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre is the only glucose sensing technology available in Canada to remotely monitor glucose status in an expectant mother to reduce exposure to COVID-19.
Top Ranked Growth Stocks to Buy for March 3rd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 3rd
Zacks.com featured highlights include: Owens & Minor, Sturm Ruger & Company, Natus Medical, Penumbra and Toyota Motor
by Zacks Equity Research
Zacks.com featured highlights include: Owens & Minor, Sturm Ruger & Company, Natus Medical, Penumbra and Toyota Motor
Medtronic's (MDT) Market Share Grows Amid COVID-19 Woes
by Zacks Equity Research
In Coronary, the ongoing issue related to the China drug-eluting stent national tender, Medtronic (MDT) is currently winning share globally.
Thermo Fisher (TMO) Buys Mesa Biotech, Grows in Point of Care
by Zacks Equity Research
Mesa Biotech's point-of-care platform is likely to help Thermo Fisher (TMO) rapidly scale up manufacturing volume amid the pandemic.
Top Ranked Growth Stocks to Buy for March 1st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 1st
New Strong Buy Stocks for March 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.